Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways. The three ...
The FDA has granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A, also known as ABBV-400), an ...
Target high-unmet-need niches—post-immunotherapy resistance, rare biomarkers and early-stage disease—while tracking therapy uptake, pricing and market access.Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ...
A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
MedPage Today on MSN
Chemo-Free Regimen May Be Effective Option for EGFR-Mutant Lung Cancer
Phase II study shows promise in setting of third-generation EGFR TKI resistance ...
A new review in the Journal of Translational Medicine maps how non-small cell lung cancer rewires lipid metabolism to fuel ...
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 ...
Oct 6 (Reuters) - ArriVent BioPharma said on Tuesday its therapy to treat patients with a type of lung cancer did not meet the main goal in a late-stage trial. The company's shares were halted in ...
ArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine ...
Oct 6 (Reuters) - ArriVent BioPharma said on Tuesday its oral therapy to treat patients with a rare type of lung cancer did not meet the main goal of delaying disease progression in a late-stage trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results